Search Results 1781-1790 of 18449 for Immunode

1. Aging and Immune Decline: Destiny or Dynamic?

   The human immunodeficiency virus attacks a type of T cell and turns them into virus factories. The immune system can still provide some protection for the ...

2. A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer - Mayo Clinic

   Subjects with known positive human immunodeficiency virus (HIV) status. History of stroke or transient ischemic attack =< 6 months prior to registration ...

3. A Phase Ⅲ Study Of Rilvegostomig In Combination With Fluoropyrimidine And Trastuzumab Deruxtecan As The First-line Treatment For HER2-positive Gastric Cancer - Mayo Clinic

   Has a known history of active primary immunodeficiency, uncontrolled active HIV infection with serologic evidence of viral infection within 28 days of C1D1.

4. Study of BIIB092 in Participants With Progressive Supranuclear Palsy - Mayo Clinic

   Known history of human immunodeficiency virus infection. Recent (within 6 months of study treatment administration) drug or alcohol abuse as defined in ...

5. A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors - Mayo Clinic

   Known active Infection with human immunodeficiency virus (HIV), hepatitis B (HBV), or hepatitis C virus (HCV): a. Patients with HIV are excluded. a.b. ...

6. Non-Hodgkin lymphoma - Symptoms and causes - Mayo Clinic

   These infections include human immunodeficiency virus (HIV), Epstein-Barr virus, human T-lymphotropic virus 1 (HTLV-1), Helicobacter pylori (H. pylori) and ...

7. A Study to Evaluate Safety of Enapotamab Vedotin in Patients with Solid Tumors - Mayo Clinic

   Known human immunodeficiency virus seropositivity. Known history / positive serology for hepatitis B (unless immune due to vaccination or resolved natural ...

8. Publications - Emily R. Levy, M.D. - Mayo Clinic

   ... immunodeficiency: a case report and literature review. BMC Infect Dis. 2024 Nov 14; 24 (1):1296. View PubMed; Rowan CM, LaBere B, Young CC, Zambrano LD ...

9. A Study to Evaluate Effectiveness and Safety of Ustekinumab Re-induction Therapy in Participants With Moderate to Severely Active Crohn's Disease (POWER) - Mayo Clinic

   Known to be infected with human immunodeficiency virus, hepatitis B, or hepatitis C. Severe, progressive, or uncontrolled renal, hepatic, hematological ...

10. A Study to Evaluate DS-8201a Combined with Olaparib in HER2-Expressing Cancers with Expansion in Endometrial Cancer Patients Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Endometrial Cancer - Mayo Clinic

    Patients who are Human Immunodeficiency Virus (HIV) positive may participate IF they meet the following eligibility requirements: They must be stable on ...